Prelude Therapeutics Incorporated
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
Last updated:
Abstract:
The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described. ##STR00001## ##STR00002##
Status:
Grant
Type:
Utility
Filling date:
20 Feb 2018
Issue date:
11 Jan 2022